CY1105949T1 - Νευροτροφικος αυξητικος παραγοντας - Google Patents

Νευροτροφικος αυξητικος παραγοντας

Info

Publication number
CY1105949T1
CY1105949T1 CY20071100092T CY071100092T CY1105949T1 CY 1105949 T1 CY1105949 T1 CY 1105949T1 CY 20071100092 T CY20071100092 T CY 20071100092T CY 071100092 T CY071100092 T CY 071100092T CY 1105949 T1 CY1105949 T1 CY 1105949T1
Authority
CY
Cyprus
Prior art keywords
growth factor
neurotrophic growth
bioprecursor
organism
derivative
Prior art date
Application number
CY20071100092T
Other languages
English (en)
Inventor
Hugo Alfonso Geerts
Stefan Leo Jozef Masure
Theo Frans Meert
Miroslav Cik
Luc August Laurentius Ver Donck
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105949(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9815283.8A external-priority patent/GB9815283D0/en
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1105949T1 publication Critical patent/CY1105949T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Αποκαλύπτεται ένα απομονωμένο μόριο νουκλεϊκού οξέος που κωδικοποιεί έναν ανθρώπινο νευροτροφικό αυξητικό παράγοντα που ορίζεται ως enovin και που έχει την αμινοξική αλληλουχία που απεικονίζεται στο Σχέδιο 1, 21, 23 ή 24 ή που κωδικοποιεί ένα λειτουργικό ισοδύναμο, παράγωγο ή βιοπρόδρομο του εν λόγω αυξητικού παράγοντα. Ο αυξητικός παράγοντας κατά προτίμηση περιλαμβάνει την αμινοξική αλληλουχία από τη θέση 27 έως 139 της αλληλουχίας που απεικονίζεται στο Σχέδιο 1, ή ένα λειτουργικό ισοδύναμο, παράγωγο ή βιοπρόδρομο αυτής. Το μόριο νουκλεϊκού οξέος που κωδικοποιεί το enovin μπορεί να χρησιμοποιηθεί για το μετασχηματισμό ενός κυττάρου, ιστού ή οργανισμού ξενιστή εφόσον συμπεριληφθεί σ' ένα κατάλληλο όχημα. Το κύτταρο, ο ιστός ή ο οργανισμός ξενιστή και το όχημα αποτελούν επίσης τμήμα της εφεύρεσης.
CY20071100092T 1998-07-14 2007-01-25 Νευροτροφικος αυξητικος παραγοντας CY1105949T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815283.8A GB9815283D0 (en) 1998-07-14 1998-07-14 Neurotrophic growth factor
US24877299A 1999-02-12 1999-02-12
US32766899A 1999-06-08 1999-06-08
PCT/EP1999/005031 WO2000004050A2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor

Publications (1)

Publication Number Publication Date
CY1105949T1 true CY1105949T1 (el) 2011-04-06

Family

ID=27269394

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071100092T CY1105949T1 (el) 1998-07-14 2007-01-25 Νευροτροφικος αυξητικος παραγοντας
CY20141100535T CY1115496T1 (el) 1998-07-14 2014-07-16 Νευροτροφικος αυξητικος παραγοντας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20141100535T CY1115496T1 (el) 1998-07-14 2014-07-16 Νευροτροφικος αυξητικος παραγοντας

Country Status (28)

Country Link
US (1) US7544788B2 (el)
EP (2) EP1640381B1 (el)
JP (2) JP4469500B2 (el)
KR (2) KR100773776B1 (el)
CN (1) CN1243770C (el)
AT (1) ATE343594T1 (el)
AU (1) AU768472B2 (el)
BG (1) BG65518B1 (el)
BR (2) BR9912819A (el)
CA (1) CA2333910C (el)
CY (2) CY1105949T1 (el)
CZ (1) CZ303868B6 (el)
DE (1) DE69933771T2 (el)
DK (2) DK1097167T3 (el)
ES (2) ES2275349T3 (el)
HK (2) HK1045528B (el)
HR (1) HRP20010036B1 (el)
HU (1) HU226073B1 (el)
ID (1) ID27024A (el)
IL (1) IL140877A0 (el)
NO (1) NO331809B1 (el)
NZ (1) NZ509723A (el)
PL (1) PL209952B1 (el)
PT (2) PT1097167E (el)
SI (1) SI1640381T1 (el)
SK (1) SK287361B6 (el)
TR (1) TR200100074T2 (el)
WO (1) WO2000004050A2 (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1311818A (zh) * 1998-07-06 2001-09-05 恩斯吉恩有限公司 神经营养因子
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
KR100773776B1 (ko) * 1998-07-14 2007-11-12 얀센 파마슈티카 엔.브이. 신경친화성 성장 인자
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU2002232785B2 (en) * 2000-12-22 2006-05-18 Genentech, Inc. Use of artemin, a member of the GDNF ligand family for preparing a neuroprotective medicament
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
AU2002250203B2 (en) * 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
KR101108014B1 (ko) * 2002-05-17 2012-01-25 티오가 파마슈티칼스, 인코포레이티드 선택성 아편제 수용체 조절인자로서 효과적인 화합물의 용도
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
ATE478092T1 (de) 2003-06-10 2010-09-15 Nsgene As Verbesserte sekretion von neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
AU2005277227B2 (en) * 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
MX2007002029A (es) * 2004-08-19 2007-03-28 Biogen Idec Inc Variantes de neublastina.
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
WO2008097927A2 (en) 2007-02-06 2008-08-14 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
CA2685686A1 (en) 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Neublastin polypeptides for use increasing vascularization in a tissue
CA2691166A1 (en) * 2007-06-27 2008-12-31 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US11225689B2 (en) * 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
KR100773776B1 (ko) * 1998-07-14 2007-11-12 얀센 파마슈티카 엔.브이. 신경친화성 성장 인자
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) † 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP2002051906A (ja) * 2000-08-11 2002-02-19 Nippon Platec Co Ltd Ｉｈ調理器による加熱を可能にしたアルミ箔材料及びこのアルミ箔材料を用いて成形したアルミ箔材料製食品用容器
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
WO2018191688A2 (en) † 2017-04-14 2018-10-18 Johnson Controls Techology Company Thermostat with exhaust fan control for air quality and humidity control

Also Published As

Publication number Publication date
NO331809B1 (no) 2012-04-10
SK142001A3 (en) 2002-02-05
DK1097167T3 (da) 2007-03-12
HUP0102821A2 (hu) 2001-11-28
EP1640381A2 (en) 2006-03-29
HK1045528A1 (en) 2002-11-29
US20050233359A1 (en) 2005-10-20
DK1640381T3 (da) 2014-07-14
CA2333910C (en) 2016-11-15
BRPI9912819B8 (pt) 2021-05-25
HRP20010036B1 (en) 2010-06-30
CZ200128A3 (cs) 2001-08-15
AU768472B2 (en) 2003-12-11
JP4469500B2 (ja) 2010-05-26
US7544788B2 (en) 2009-06-09
BG105107A (en) 2001-10-31
SI1640381T1 (sl) 2014-07-31
BRPI9912819B1 (pt) 2018-09-18
CA2333910A1 (en) 2000-01-27
EP1097167B2 (en) 2018-12-12
NZ509723A (en) 2004-01-30
CZ303868B6 (cs) 2013-06-05
NO20010212L (no) 2001-03-14
ID27024A (id) 2001-02-22
JP2010158241A (ja) 2010-07-22
ES2275349T3 (es) 2007-06-01
HUP0102821A3 (en) 2003-09-29
EP1097167B1 (en) 2006-10-25
HRP20010036A2 (en) 2001-12-31
KR20060061408A (ko) 2006-06-07
TR200100074T2 (tr) 2001-11-21
SK287361B6 (sk) 2010-08-09
PT1097167E (pt) 2007-02-28
BG65518B1 (bg) 2008-10-31
IL140877A0 (en) 2002-02-10
DE69933771T2 (de) 2007-09-13
PL209952B1 (pl) 2011-11-30
PT1640381E (pt) 2014-07-17
PL348431A1 (en) 2002-05-20
HU226073B1 (en) 2008-04-28
HK1045528B (zh) 2006-10-27
EP1097167A2 (en) 2001-05-09
KR20010083108A (ko) 2001-08-31
EP1640381B1 (en) 2014-05-14
NO20010212D0 (no) 2001-01-12
AU5283299A (en) 2000-02-07
CN1243770C (zh) 2006-03-01
KR100712223B1 (ko) 2007-04-27
DE69933771D1 (de) 2006-12-07
EP1640381A3 (en) 2007-01-31
CY1115496T1 (el) 2017-01-04
WO2000004050A3 (en) 2000-11-09
BR9912819A (pt) 2001-05-02
CN1342165A (zh) 2002-03-27
HK1092477A1 (en) 2007-02-09
JP2002520042A (ja) 2002-07-09
KR100773776B1 (ko) 2007-11-12
ES2479067T3 (es) 2014-07-23
JP4624476B2 (ja) 2011-02-02
WO2000004050A2 (en) 2000-01-27
ATE343594T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
CY1105949T1 (el) Νευροτροφικος αυξητικος παραγοντας
DE60035337D1 (de) Humane Peptide/Proteine, die das Töten von Zellen, einschliesslich lymphoide Tumorzellen, herbeiführen oder bewirken
CY1115405T1 (el) Αλληλουχιες κυκλοϊου που συνδyαζονται με την ασθενεια της καχεξιας του χοιριδιου (map)
PT1359222E (pt) Factor viii hibrido humano/suino
DK478786A (da) Cystein-forarmede muteiner af biologisk aktive humantumornekrosefaktorproteiner
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
TR199802651T2 (xx) Piridilalken, Piridil-Alkin Asit Amidleri
FR2741806B1 (fr) Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
CY1106049T1 (el) Παραγωγα ινδολης
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DK381189D0 (da) N-2,3-butadienyl-tri- og -tetraaminoalkanderivater og deres anvendelse
EA200100700A1 (ru) Гены и белки и их применение
DE59010164D1 (de) Wässrige Polymerisatzubereitungen
ES2072749T5 (es) Diagnostico de la hipertermia maligna porcina.
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DE60126602D1 (de) Neue collectine
ATE92070T1 (de) Azachromanderivate.
SE9604439D0 (sv) New receptor
DK420187A (da) Oxiran-pseudooligosaccharider, deres fremstilling og anvendelse
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
BR9808012A (pt) Genes isolados e proteìnas codificando resistência a fotossensibilizadores
ES2123311T3 (es) Compuestos tetrakisazoicos, su preparacion y empleo como colorantes.
RU97118243A (ru) Вакцина против бруцеллеза крупного рогатого ската